StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Insys Therapeutics (INSY) Receives CRL from FDA on Buprenorphine NDA
July 27, 2018 12:51 PM
INSYS Therapeutics, Inc. (NASDAQ: INSY) announced that today it received a Complete Response Letter (CRL) from the U.S. Food and ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
Insys Therapeutics (INSY) Falls 8% Following CRL
July 27, 2018 12:59 PM
INSYS Therapeutics Receives Complete Response Letter from FDA for Buprenorphine NDA
July 27, 2018 12:50 PM